Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-10T16:49:28.190Z Has data issue: false hasContentIssue false
  • English
  • Français

Quality of life in body dysmorphic disorder

Published online by Cambridge University Press:  03 September 2012

Waguih William IsHak ,
Michael A. Bolton ,
Jean-Charles Bensoussan ,
George V. Dous ,
Trang T. Nguyen ,
Allycin L. Powell-Hicks ,
Jennifer E. Gardner  and
Kimberly M. Ponton
Waguih William IsHak*
Affiliation:
Cedars-Sinai Medical Center, Los Angeles, California, USA David Geffen School of Medicine at University of California–Los Angeles, Los Angeles, California, USA
Michael A. Bolton
Affiliation:
Massachusetts General Hospital, Boston, Massachusetts, USA
Jean-Charles Bensoussan
Affiliation:
Cedars-Sinai Medical Center, Los Angeles, California, USA
George V. Dous
Affiliation:
Cedars-Sinai Medical Center, Los Angeles, California, USA
Trang T. Nguyen
Affiliation:
University of California–Los Angeles, Los Angeles, California, USA
Allycin L. Powell-Hicks
Affiliation:
Cedars-Sinai Medical Center, Los Angeles, California, USA
Jennifer E. Gardner
Affiliation:
Keck School of Medicine at University of Southern California, Los Angeles, California, USA
Kimberly M. Ponton
Affiliation:
David Geffen School of Medicine at University of California–Los Angeles, Los Angeles, California, USA
*
*Address for correspondence: Waguih William IsHak, MD, FAPA, Director, Psychiatry Residency Training Program, and Medical Student Education in Psychiatry at Cedars-Sinai Medical Center (CSMC), and Associate Clinical Professor of Psychiatry at UCLA and CSMC, Cedars-Sinai Medical Center, 8730 Alden Drive, Thalians W-157, Los Angeles, CA 90048. *This information is correct. (Email Waguih.Ishak@cshs.org)
Get access Rights & Permissions [Opens in a new window]

Abstract

Body dysmorphic disorder (BDD) has a significant impact on the patients’ quality of life (QOL). This is an initial literature review of QOL in patients with BDD, examining the extent of QOL impairments, the impact of psychiatric comorbidity on QOL, and the effect of treatment on QOL in BDD. Studies were identified through PubMed, MEDLINE, and PsycINFO searches from 1960–2011 using the keywords: “quality of life,” “body dysmorphic disorder,” “dysmorphophobia,” and “body image.” Studies included in this review were selected using specific criteria by two authors reaching consensus. Most BDD research studies have used symptom severity measures mainly to study BDD and its treatments. BBD with or without comorbidities is significantly associated with poor QOL and functioning. Studies show that treatment of BDD, either by psychopharmacological treatments such as selective serotonin reuptake inhibitors (SSRIs) or cognitive behavior therapy, might have positive effects on QOL, although these results need to be replicated in larger studies. In conclusion, QOL could add significant value to the assessment of BDD if used as one of the primary measures in research and clinical work in BDD, by providing more information and clearer understanding on the impact of the illness on satisfaction with activities of daily life and overall sense of wellbeing before and after treatment.

Keywords

Body dysmorphic disorderbody imagedysmorphophobiaquality of life
Type
Review Article
Information
CNS Spectrums , Volume 17 , Issue 4 , December 2012 , pp. 167 - 175
Copyright
Copyright © Cambridge University Press 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

The authors would like to express their deep appreciation to Katharine Phillips, MD, for her feedback during the early development of this manuscript, and for her groundbreaking work in body dysmorphic disorder.

References

1.American Psychiatric Association. Diagnostic and Statistical Manual, 4th ed., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Press, Inc.; 2000.Google Scholar
2.Rief, W, Buhlmann, U, Wilhelm, S, Borkenhagen, A, Brähler, E. The prevalence of body dysmorphic disorder: a population-based survey. Psychol Med. 2006; 36(6): 877–885.CrossRefGoogle ScholarPubMed
3.Faravelli, C, Salvatori, S, Galassi, F, etal. Epidemiology of somatoform disorders: a community survey in Florence. Soc Psychiatry Psychiatr Epidemiol. 1997; 32(1): 24–29.Google ScholarPubMed
4.Ruffolo, JS, Phillips, KA, Menard, W, Fay, C, Weisberg, RB. Comorbidity of body dysmorphic disorder and eating disorders: severity of psychopathology and body image disturbance. Int J Eat Disord. 2006; 39(1): 11–19.CrossRefGoogle ScholarPubMed
5.Phillips, K, Menard, W, Fay, C. Gender similarities and differences in 200 individuals with body dysmorphic disorder. Compr Psychiatry. 2006; 47(2): 77–87.CrossRefGoogle ScholarPubMed
6.Koran, LM, Abujaoude, E, Large, MD, Serpe, RT. The prevalence of body dysmorphic disorder in the United States adult population. CNS Spectr. 2008; 13(4): 316–322.CrossRefGoogle ScholarPubMed
7.Phillips, K, Dufresne, RG Jr. Body dysmorphic disorder: a guide for primary care physicians. Prim Care. 2002; 29(1): 99–111.CrossRefGoogle ScholarPubMed
8.Phillips, KA. Quality of life for patients with body dysmorphic disorder. J. Nerv Ment Dis. 2000; 188(3): 170–175.CrossRefGoogle ScholarPubMed
9.Phillips, KA, Menard, W, Fay, C, Pagano, ME. Psychosocial functioning and quality of life in body dysmorphic disorder. Compr Psychiatry. 2005; 46(4): 254–260.CrossRefGoogle ScholarPubMed
10.Veale, D. Body dysmorphic disorder. Postgrad Med J. 2004; 80(940): 67–71.CrossRefGoogle ScholarPubMed
11.Phillips, KA, Rasmussen, SA. Change in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: a placebo-controlled study. Psychosomatics. 2004; 45(5): 438–444.CrossRefGoogle ScholarPubMed
12.Phillips, KA. Suicidality in body dysmorphic disorder. Prima Psychiatry. 2007; 14(12): 58–66.Google ScholarPubMed
13.Didie, ER, Tortolani, C, Walters, M, etal. Social functioning in body dysmorphic disorder: assessment considerations. Psychiatr Q. 2007; 77(3): 223–229.CrossRefGoogle Scholar
14.Hrabosky, JI, Cash, TF, Veale, D, etal. Multidimensional body image comparisons among patients with eating disorders, body dysmorphic disorder, and clinical controls: a multisite study. Body Image. 2009; 6(3): 155–163.CrossRefGoogle ScholarPubMed
15.Marques, L, Leblanc, N, Robinaugh, D, etal. Correlates of quality of life and functional disability in individuals with body dysmorphic disorder. Psychosomatics. 2011; 52(3): 245–254.CrossRefGoogle ScholarPubMed
16.Phillips, KA, Pagano, ME, Menard, W, Stout, RL. A 12-month follow-up study of the course of body dysmorphic disorder. Am J Psychiatry. 2006; 163(5): 907–912.CrossRefGoogle ScholarPubMed
17.Crerand, C, Phillips, K, Menard, W, Fay, C. Nonpsychiatric medical treatment of body dysmorphic disorder. Psychosomatics. 2005; 46(6): 549–555.CrossRefGoogle ScholarPubMed
18.Nachshoni, T, Kotler, M. Legal and medical aspects of body dysmorphic disorder. Med Law. 2007; 26(4): 721–735.Google ScholarPubMed
19.Coles, ME, Phillip, KA, Menard, W, etal. Body dysmorphic disorder and social phobia: cross-sectional and prospective data. Depress Anxiety. 2006; 23(1): 26–33.CrossRefGoogle ScholarPubMed
20.Grant, JE, Menard, W, Pagano, ME, Fay, C, Phillips, KA. Substance use disorders in individuals with body dysmorphic disorder. J Clin Psychiatry. 2005; 66(3): 309–316.CrossRefGoogle ScholarPubMed
21.Fals-Steward, W, Schafer, J. The treatment of substance abusers with obsessive-compulsive disorder: an outcome study. J Subst Abuse Treat. 1992; 9(4): 365–370.CrossRefGoogle Scholar
22.Gunstad, J, Phillips, KA. Axis I comorbidity in body dysmorphic disorder. Compr Psychiatry. 2003; 44(4): 270–276.CrossRefGoogle ScholarPubMed
23.Didie, ER, Walters, MM, Pinto, A, etal. A comparison of quality of life and psychosocial functioning in obsessive-compulsive disorder and body dysmorphic disorder. Ann Clin Psychiatry. 2007; 19(3): 181–186.CrossRefGoogle ScholarPubMed
24.Phillips, KA, Stout, RL. Associations in the longitudinal course of body dysmorphic disorder with major depression, obsessive compulsive disorder, and social phobia. J Psychiatr Res. 2006; 40(4): 360–369.CrossRefGoogle ScholarPubMed
25.Phillips, K, Hollander, E. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. Body Image. 2008; 5(1): 13–27.CrossRefGoogle Scholar
26.Williams, J, Hadjistavropoulos, T, Sharpe, D. A meta-analysis of psychological and pharmacological treatments for body dysmorphic disorder. Behav Res Ther. 2006; 44(1): 99–111.CrossRefGoogle ScholarPubMed
27.Grant, JE, Phillips, KA. Recognizing and treating body dysmorphic disorder. Ann Clin Psychiatry. 2005; 17(4): 205–210.CrossRefGoogle ScholarPubMed
28.Phillips, KA, Menard, W. A prospective pilot study of levetiracetam for body dysmorphic disorder. CNS Spectr. 2009; 14(5): 252–260.CrossRefGoogle ScholarPubMed